Release date: 2016-10-27 In the GEN website launched last year, "Wall Street or the nine companies to be acquired", the Medivation on the list is not surprising, and was recently acquired by Pfizer for $14 billion. This year, the GEN website once again launched "Wall Street or 10 companies to be acquired". It is reported that from January to August last year, the biotechnology industry's mergers and acquisitions, IPO, private equity and venture capital transactions totaled 655, the transaction amounted to 94.27 billion US dollars; in comparison, although this year's transactions have reached 869, but the total transaction volume Only 77.48 billion US dollars, the latter fell by 18% compared with the same period last year. In this issue's list, GEN pointed out that the small and medium-sized biopharmaceutical companies on the list will continue to be the next “Murch†of Wall Street's next acquisition, and the newly developed products or clinical programs are expected to generate billions of dollars in sales revenue. Acadia Pharmaceuticals (Acadia Pharmaceuticals) Acadia Pharmaceuticals (NASDAQ: ACAD) is a pharmaceutical company focused on central nervous system diseases (CNS) and is headquartered in San Diego, USA. Currently, the company is also evaluating the potential of Nuplazid for the treatment of other CNS diseases, including Alzheimer's-related mental illness. On April 29 this year, the company announced that its development of the Parkinson drug Nuplazid (pimavanserin) is the first drug approved by the FDA for the treatment of psychotic symptoms such as hallucinations and delusions in patients with Parkinson's (PD). As a result, the company's stock soared by 80% on the day. The drug officially entered the market in late May this year. Brian Feroldi, health analyst at The Motley Fool, said that 40% of patients with Parkinson's disease have schizophrenia complications, and there are about 150,000 to 200,000 such patients in the United States alone, and there is no better treatment in this field. The company is also studying whether Nuplazid can be used to treat psychiatric disorders in people with schizophrenia and Alzheimer's disease, and is currently in Phase II trials. If the test is successful, Nuplazid sales are expected to exceed the $3 billion mark. Brian Nichols, BNL Financial's asset appraiser, said it is possible to give Acadia a $10 billion valuation, at least $5 billion. The current valuation is too conservative, Wall Street began to re-examine the potential of Nuplazid, which provides the possibility for large companies to acquire Acadia. Michael Yee of Morningstar, an international authoritative fund rating agency, said Biogen is interested in the company, in addition to Teva Pharmaceutical, AstraZeneca, Allergan, Eli Lilly, Lundbeck, Merck, Novartis and Takeda Pharmaceutical are potential buyers of the company. Alexion Pharmaceuticals Founded in 1992, Yali Brothers is a biopharmaceutical company. The company is committed to innovative therapeutic products that provide medical care for critically ill patients and patients with ultra-rare diseases. The company's products are the first and only treatment for two serious super rare diseases: life-threatening and ultra-rare hereditary blood diseases - paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Bloomberg and Reuters reported last month that Roche is exploring the acquisition of Alexion's financing options. Since Roche did not immediately deny the report, CNBC's Jim Cramer and TheStreet.com predict that the pharmaceutical giant Roche will eventually buy Alexion. Other market watchers also predict that Alexion will eventually be acquired, but they have not yet said that Roche is the only potential buyer. Alexion's "Dahua Hua Dan" is the rare disease drug Soliris? (eculizumab), known as "the world's most expensive medicine", can be used to treat blood diseases that cause organ failure - atypical hemolytic uremic syndrome (aHUS) And paroxysmal nocturnal hemoglobinuria (PNH). Soliris' estimated sales have reached about $1.5 billion and will soar to $3 billion to $6 billion this year. This year, Alexion's overall sales exceeded analysts' expectations. Soliris achieved sales of $1.366 billion in the first half of this year, up 10.5% from the same period last year, despite the company's rare metabolic disease, Strensiq? Asumatase alfa) and Kanuma® (sebelipase alfa) for long-term enzyme replacement therapy (ERT) in patients with lysosomal acid lipase deficiency (LAL-D) have also been listed, but Soliris still accounts for 94% of the company's total income. Ardelyx Ardelyx is a clinical biopharmaceutical company dedicated to the development of non-systematic small molecule drug therapy. The company was founded in Delaware on October 17, 2007 and changed to Ardelyx by Nteryx in June 2008. On July 21 this year, the hyperkalemia drug company Relypsa was eventually acquired by Galenica for $1.53 billion in cash after seeking buyers. The company has a product that is very similar to the Relypsa home Veltassa?, and analysts expect Ardelyx to seek buyers soon. Unfortunately, the company's heavy-duty drug tenapanor encountered Waterloo in the clinical phase IIa study of clinical stage 3 and type 2 diabetes in chronic kidney disease, and AstraZeneca signed value with tendenor in 2012 with Ardelyx. A $270 million cooperation agreement. The company is now exploring the relevance of tenapanor in the treatment of chronic kidney disease and irritable bowel syndrome. Biogen Biogen Idec sets new standards in care for oncology, neurology and immunology. As a global leader in the development, production and marketing of innovative therapies, Biogen Idec is able to transform scientific discoveries into advances in human health care. It was formed by the merger of biotech company Biogen and pharmaceutical company Idec in November 2003. Headquartered in Massachusetts, USA, with branches in Europe, Canada, Australia and Japan. It mainly develops cancer, psychosis, skin diseases and rheumatism related drugs. The Wall Street Journal quoted anonymous sources as saying that the company had acquired the "Olive Branch" from Merck & Co and Allergan. BioMarin Pharmaceutical Bayerin Pharmaceuticals is a biotechnology pharmaceutical company with Naglazyme (fused enzyme), Kuvan (sapropterin dihydrochloride), Firdapse (amimidyl phosphate) and Aldurazyme (Lalonizyme). As early as 2013, Roche handed out the "Olive Branch" to the company and wanted to acquire BioMarin for $15 billion. In July of this year, the industry passed Roche Pharmaceuticals' acquisition of Baimailin Pharmaceuticals, which caused the latter's share price to rise by nearly 10%. Gilead Sciences Headquartered in Foster, California, Gilead Sciences was founded in 1987 to research and commercialize and commercialize therapies and treatments for the treatment of viral diseases. Products include Viread, Emriva and Truvada for the treatment of human immunodeficiency virus infection; Hepsera for the treatment of chronic hepatitis B virus infection; AmBisome for the treatment of fungal infections; Vistide for the treatment of cytomegalovirus infection, and for Treatment of AIDS-related Kaposi's sarcoma liposomal daunorubicin preparation DaunoXome. In addition, the company offers Tamiflu for the treatment of influenza and Macugen for the treatment of neovascular age-related macular degeneration. On September 21, Gilead announced the discontinuation of antibody GS-5745 for clinical phase II/III studies of moderate to severe active ulcerative colitis. Sean Williams, an analyst at The Motley Fool, said Pfizer and Merck are interested in acquiring Gilead. Incyte Inc. is located in Wilmington, Delaware, USA, and is principally engaged in the development and sale of cancer treatment and inflammatory treatment products with independent intellectual property rights. It is listed on NASDAQ under the symbol ENSY. In recent years, Incyte has been ranked seventh in the world by Forbes magazine as “the most innovative company in the worldâ€. On September 1, 2015, Jiangsu Hengrui Medicine and Incyte reached an agreement in the United States to license the PD-1 monoclonal antibody (code name "SHR1210") for the tumor immunotherapy with the former intellectual property rights to the US Incyte company. . New drug Roxolitinib for the treatment of rare blood diseases, Incyte has its rights in the US market, and the global market sales rights outside the US will be held by Novartis. Analysts said that Gilead intends to acquire Incyte. Intercept Pharmaceuticals Registered in Delaware on September 4, 2002, Intercept is a developmental pharmaceutical company focused on the development and marketing of new treatments for chronic liver disease using its proprietary bile acid chemistry, 2012 Listed on NASDAQ. Intercept pharmaceutical company's obeticholic acid treatment area is primary biliary cirrhosis, which belongs to the therapeutic category, and non-alcoholic steatohepatitis will be the main indication for the drug in the future. Market analysts and observers' attention to non-alcoholic fatty liver drugs (NASH) naturally won't let them miss Intercept, the "dark horse." As early as February this year, Reuters quoted anonymous sources as saying that the company is considering selling itself to interested buyers. Last month, the company's leading candidate, ocaliva® (obeticholic acid), entered NASH's Phase III clinical trial, ahead of Phase II clinical trials of Gilead Sciences' NASH peer candidate, simtuzumab. The Investor's Business Daily said that the combination of the two will be an important part of the future treatment model, so Intercept is a very attractive target. RBC Capital Markets analyst Michael Yee believes the company's valuation is between $5 billion and $10 billion. Kite Pharma (Kite Pharma) Kite has been a leader in the CAR-T field, and KTE-C19 has been tested in a variety of cancers and has received FDA-approved treatment of refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and Breakthrough therapy certification for transformed follicular lymphoma. On the one hand, last month's candidate product KTE-C19 demonstrated positive results in the Phase II trial of the clinical phase I/II trial of non-Hodgkin's lymphoma (NHL), and is expected to obtain a biologics license application by the end of the year. On the other hand, in July this year, Juno reported that four patients died in their CAR-T related trials. Juno's tripping made Kite hope to become NO.1 in the CAR-T competition field. Many large pharmaceutical companies are Interested in acquiring it. Tesaro Tesaro is a growth biotech company focused on cancer treatment and is headquartered in Waltham, Massachusetts, USA. As a biopharmaceutical company in a period of growth and expansion, the company's antiemetic drugs are mainly used to prevent delayed nausea and vomiting associated with chemotherapy for emetogenic cancer. At the end of June this year, Tesaro (NASDAQ:TSRO) shares more than doubled since the market opened, from $37 to $77, and now the company's share price has exceeded $120. All of this was due to the release of Phase III clinical trial data from its new anti-cancer drug Niraparib. The results were somewhat unexpectedly good, which made the investment market expect a lot. Niraparib, a targeted drug targeting the PARP gene, targets cancers with BRCA1/2 mutations, such as ovarian and breast cancer. Currently, Tesaro has been listed as a possible acquisition by several biopharmaceutical giants including Amgen, New Base, Pfizer and Gilead. Source: Bio-Exploration Bluetooth TWS hearing earphones for impairment Shenzhen Sunshine Technology Co.,Ltd , https://www.yatwin.com
These 10 biopharmaceutical companies are the next "Murch" of Wall Street's acquisition.